#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Acromegaly and pharmacotherapy – editorial


Authors: Michal Kršek
Authors‘ workplace: III. interní klinika - klinika endokrinologie a metabolizmu 1. LF UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA
Published in: Vnitř Lék 2015; 61(2): 95-96
Category: Editorial


Sources

1. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004; 89(2): 667–674.

2. Fahlbusch R, Honegger J, Buchfelder M. Evidence supporting surgery as treatment of choice for acromegaly. J Endocrinol 1997; 155(Suppl 1): S53-S55.

3. Lamberts SW, Zweens M, Verschoor L et al. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201–995, bromocriptine, and the combination of both drugs. J Clin Endocrinol Metab 1986; 63(1): 16–19.

4. Trainer PJ, Drake WM, Katznelson L et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000; 342(16): 1171–1177.

5. Petersenn S, Schopohl J, Barkan A et al. Pasireotide Acromegaly Study Group. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab 2010; 95(6): 2781–2789.

6. Jezková J, Marek J, Hána V et al. Gamma knife radiosurgery for acromegaly: long-term experience. Clin Endocrinol (Oxf) 2006; 64(5): 588–595.

7. Wattson DA, Tanguturi SK, Spiegel DY et al. Outcomes of proton therapy for patients with functional pituitary adenomas. Int J Radiat Oncol Biol Phys 2014; 90(3): 532–539.

Labels
Diabetology Endocrinology Internal medicine

Article was published in

Internal Medicine

Issue 2

2015 Issue 2

Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#